摘要
目的探讨不同剂量阿托伐他汀对经皮冠脉介入治疗(PCI)术后心肌损伤及心脏型脂肪酸结合蛋白(H-FABP)的影响。方法选取2017年1月-12月西安市中心医院心内科符合PCI治疗指征的冠心病患者100例,参照随机数字表法分为常规剂量组、强化剂量组,每组50例。常规剂量组围术期及术后6个月每日服用20 mg阿托伐他汀,强化剂量组围术期及术后6个月每日服用40 mg阿托伐他汀。比较2组患者术后血清肌酸激酶同工酶(CK-MB)、肌钙蛋白I(CTnI)、H-FABP、左心室射血分数(LVEF)水平变化以及心力衰竭发生率。结果2组患者术后血清CK-MB和CTnI水平均较术前明显升高,且常规剂量组高于强化剂量组,差异有统计学意义(P<0.05);2组患者术后血清H-FABP水平均较术前明显升高,且常规剂量组高于强化剂量组,差异有统计学意义(P<0.05)。2组心力衰竭发生率比较差异无统计学意义(P>0.05)。2组患者术后LVEF水平均较术前明显上升,且强化剂量组高于常规剂量组,差异有统计学意义(P<0.05)。结论PCI术前及术后服用强化剂量阿托伐他汀能明显减轻心肌损伤,促进左心室功能恢复,改善患者症状和预后。
Objective To evaluate the effect of different doses of atorvastat on myocardial damage and H-FABP after PCI.Methods From January 2017 to December 2017,100 coronary heart disease patients in PCI were selected in our hospital.According to random number table,they were divided into routine and high dose group,with 50 patients in each group.The routine drug group was treated with 20 mg of atorvastatin daily for the perioperative and 6 months after PCI,the high group was treated with 40 mg of atorvastatin daily for the perioperative and 6 months after PCI.The serum levels of CK-MB,CTn I,H-FABP,LVEF and event of heart failer were compared among the two groups after PCI.Results The level of serum CK-MB and CTn I in two groups after PCI was significantly higher than before PCI,and the level of serum CK-MB and CTn I in the routine group was significantly higher than in the high dose group(P<0.05).The level of serum H-FABP in two groups after PCI was significantly higher than before PCI,and the level of serum H-FABP in the routine group was significantly higher than in the high dose group(P<0.05),the difference of heart failure between the two groups was not statistically significant(P>0.05).The level of LVEF in two groups after PCI was significantly higher than before PCI,and the level of LVEF in the high dose group was significantly higher than in the routine group(P<0.05).Conclusion Before and after PCI,treatment of high-dose atorvastatin could effectively reduce myocardial damage,improve heart function,better protect myocardium.
作者
张涛
慕玉东
邬小平
曹永胜
吴冠吉
Zhang Tao;Mu Yudong;Wu Xiaoping(The Central Hospital of Xi'an City,Xi'an,shaanxi 710003;The Shaanxi Province Cancer Hospital,Xi'an,Shaanxi 710061)
出处
《基层医学论坛》
2020年第4期452-454,共3页
The Medical Forum
基金
陕西省重点研发计划项目(2019SF-189)
西安市科技计划项目[2017114SF/YX008(6)]
关键词
经皮冠脉介入治疗
阿托伐他汀
不同剂量
H-FABP
心肌损伤
影响
Percutaneous coronary intervention
Atorvastatin
Different dose
Heart fatty acid-binding protein
Myocardial damage
Influence
